Biblio
“Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals.”, J Alzheimers Dis, vol. 62, no. 2, pp. 487-498, 2018.
, “Decreased Prefrontal Activation during Matrix Reasoning in Predementia Progranulin Mutation Carriers.”, J Alzheimers Dis, vol. 62, no. 2, pp. 583-589, 2018.
, “Cognitive Impairment Is a Common Comorbidity in Deceased COVID-19 Patients: A Hospital-Based Retrospective Cohort Study.”, J Alzheimers Dis, vol. 78, no. 4, pp. 1367-1372, 2020.
, “Environmental Nanoparticles, SARS-CoV-2 Brain Involvement, and Potential Acceleration of Alzheimer's and Parkinson's Diseases in Young Urbanites Exposed to Air Pollution.”, J Alzheimers Dis, vol. 78, no. 2, pp. 479-503, 2020.
, “Life Course Air Pollution Exposure and Cognitive Decline: Modelled Historical Air Pollution Data and the Lothian Birth Cohort 1936.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1063-1074, 2021.
, “Could Altered Evoked Pain Responsiveness Be a Phenotypic Biomarker for Alzheimer's Disease Risk? A Cross-Sectional Analysis of Cognitively Healthy Individuals.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1227-1233, 2021.
, “Quality of Life in Advanced Dementia with Late Onset, Young Onset, and Very Young Onset.”, J Alzheimers Dis, vol. 80, no. 1, pp. 283-297, 2021.
, “Neuropsychiatric Symptoms in Patients with Dementia Associated with Increased Psychological Distress in Caregivers During the COVID-19 Pandemic.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1705-1712, 2021.
, “Impact of Social Isolation on People with Dementia and Their Family Caregivers.”, J Alzheimers Dis, vol. 81, no. 2, pp. 607-617, 2021.
, “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation.”, J Alzheimers Dis, vol. 81, no. 4, pp. 1505-1527, 2021.
, “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
, “Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1061-1074, 2022.
, “Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil.”, J Alzheimers Dis, vol. 90, no. 1, pp. 161-172, 2022.
, “How Do Persons with Young and Late Onset Dementia Die?”, J Alzheimers Dis, vol. 81, no. 2, pp. 843-852, 2021.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Pain Assessment in Elderly with Behavioral and Psychological Symptoms of Dementia.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1217-25, 2016.
, “Comparing the Effects of Multisensory Stimulation and Individualized Music Sessions on Elderly People with Severe Dementia: A Randomized Controlled Trial.”, J Alzheimers Dis, vol. 52, no. 1, pp. 303-15, 2016.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “A Meta-Analysis of Alzheimer's Disease Incidence and Prevalence Comparing African-Americans and Caucasians.”, J Alzheimers Dis, vol. 50, no. 1, pp. 71-6, 2016.
, “The Role of Ethnicity in Alzheimer's Disease: Findings From The C-PATH Online Data Repository.”, J Alzheimers Dis, vol. 51, no. 2, pp. 515-23, 2016.
, “Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.”, J Alzheimers Dis, vol. 49, no. 4, pp. 991-1003, 2016.
, “Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 815-824, 2018.
, “Plasma Biomarkers of Alzheimer's Disease in African Americans.”, J Alzheimers Dis, vol. 79, no. 1, pp. 323-334, 2021.
, “Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.”, J Alzheimers Dis, vol. 49, no. 4, pp. 991-1003, 2016.
, “Age and its association with low insulin and high amyloid-β peptides in blood.”, J Alzheimers Dis, vol. 49, no. 1, pp. 129-37, 2016.
,